Back to today’s briefing

Story perspectives

FDA Approves $3.1M Gene Therapy for Rare Skin Disorder

5/1/2025

39 6

Summary

Story summary

Abeona Therapeutics has received FDA approval for Zevaskyn, a groundbreaking gene therapy aimed at treating recessive dystrophic epidermolysis bullosa (RDEB), a debilitating skin condition. Priced at $3.1 million, this innovative treatment promises remarkable wound healing and pain relief. Launching in qualified centers by Q3 2025, it will be backed by a dedicated patient services program.

1 of 1

Story summary

Abeona Therapeutics has received FDA approval for Zevaskyn, a groundbreaking gene therapy aimed at treating recessive dystrophic epidermolysis bullosa (RDEB), a debilitating skin condition. Priced at $3.1 million, this innovative treatment promises remarkable wound healing and pain relief. Launching in qualified centers by Q3 2025, it will be backed by a dedicated patient services program.